Ocular Therapeutics shares are trading higher after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutics shares are trading higher after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.
June 20, 2024 | 11:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutics shares are experiencing a positive impact after TD Cowen upgraded the stock from Hold to Buy and increased the price target from $7 to $11.
The upgrade from Hold to Buy and the significant increase in the price target from $7 to $11 by TD Cowen is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100